$IRTC

Patterson Chad sold $884K of IRTC

Patterson Chad (CHIEF COMM & PRODUCT OFFICER) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.

Original reporting
SEC EDGAR · Patterson Chad
Published Aug 11, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

An officer’s open-market sale of $884K worth of shares is a sentiment datapoint, but it does not include any new operational, financial, or regulatory information about IRTC.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a major repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, the signal is weak.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC disclosed a Form 4 showing officer Patterson Chad sold 7,093 shares for about $884K on 2026-08-10.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and small unless follow-on selling accelerates.

Evidence & confidence

The filing is primary-source and specific, but insider sales are often routine and the article provides no accompanying company performance or guidance change.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as less “mechanical” selling, but the article still lacks evidence of distress or a broader sell signal.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Patterson Chad

    Chief Commercial and Product Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

iRhythm Completes VitalConnect Acquisition

iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.

$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.